|
For further information, please contact:
Dan Suesskind, Chief Financial Officer |
Teva Pharmaceutical Industries Ltd. |
972-2-941-1717 | |
|
George Barrett,
Corp. E. V.P. - Global pharmaceutical Markets
Chief Executive Officer |
Teva Pharmaceutical Industries Ltd. Teva North America |
(215) 591-3030 | |
|
Liraz Kalif /
Kevin Mannix, Investor Relations |
Teva Pharmaceutical Industries Ltd. Teva North America |
972-3-926-7281 (215) 591-8912 | |
|
Sven Andréasson President & CEO
|
Active Biotech
|
+46 46 19 20 49 | |
|
Tomas Leanderson Chief Scientific Officer
|
Active Biotech
|
+46 46 19 20 95 | |
|
Cecilia Hofvander Manager Corporate Communication
|
Active Biotech
|
+46 46 19 11 22 | |
INITIATION OF ENROLLMENT IN PIVOTAL PHASE III CLINICAL STUDY OF ORAL LAQUINIMOD FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS
| Source: Active Biotech
Pièces jointes
